Systematic review and meta-analysis of target terapies for the treatment of metastatic renal cancer

International Braz J Urol

Volumn 39, Issue 6, 2013, Pages 768-778

  Durán, Marcela ^a   Matheus, Wagner ^a   Ferreira, Ubirajara ^a   Clark, Otávio ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Pesquisador da Evidências Credibilidade Científica   (Brazil)

Author keywords

Kidney neoplasms; Meta analysis as topic; Tissue therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

DISEASE COURSE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; META ANALYSIS; METASTASIS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894103753     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2013.06.02     Document Type: Review

References (24)

1. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6(Suppl 1): S55-7.
2. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al.: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients withmetastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133-41. Erratum in: J Clin Oncol. 2005; 23: 2877.
3. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al.: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18: 2972-80.
4. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127-32.
5. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]: The Cochrane Collaboration; 2008. Available at: www.cochrane-handbook.org
6. The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Cochrane Collaboration; 2008. Available at: http://ims.cochrane. org/home
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-60.
8. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, et al.: Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008; 26: 3763-9.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-11.
10. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1280-9. Erratum in: J Clin Oncol. 2009; 27: 2305.
11. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al.: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysisof overall survival. J Clin Oncol. 2010; 28: 2144-50.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cellcarcinoma. J Clin Oncol. 2009; 27: 3584-90.
15. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al.: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-8.
16. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cellcarcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-43.
17. Yang S, de Souza P, Alemao E, Purvis J: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer. 2010; 102: 1456-60.
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34. Erratum in: N Engl J Med. 2007; 357: 203.
19. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56.
20. Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renalcancer. Am J Clin Oncol. 2007; 30: 220-7.
21. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-8.
22. Rexer H: First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2-AN 33/11)]. Urologe A. 2012; 51: 724-6.
23. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-9. Erratum in: Lancet. 2012; 380: 1818.
24. Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, et al.: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cellcarcinoma. J Clin Oncol. 2012; 30: 1678-85.